Edesa Licenses Paridiprubart in Japan to Kyorin for $12M Upfront, Up to ~$134M Milestones
EDSA has more than doubled off its 52-week low of $0.72.
Summary
Edesa licensed Japanese rights to paridiprubart to Kyorin for $12 million up front plus up to about $134 million in milestones and double-digit royalties, and separately terminated its H.C. Wainwright ATM effective November 16, 2026.
Key Events · M&A and Partnerships · EDSA
-
Kyorin Japan License Signed
An exclusive, royalty-bearing license grants Kyorin rights to develop and commercialize paridiprubart (EB05) for ARDS in Japan; Edesa retains all rights outside Japan and the right to manufacture.
-
$12M Upfront, ~$134M Milestones
The deal includes a one-time non-refundable $12 million upfront, up to $55 million in development and regulatory milestones and up to ¥12.0 billion in sales milestones, plus low double-digit tiered royalties on Japanese net sales.
-
Non-Dilutive Cash vs Going Concern
The $12 million upfront arrives against a previously disclosed going-concern warning that resources would not fund operations through fiscal 2026, reducing reliance on another discounted equity raise.
-
ATM Agreement Terminated
Edesa gave H.C. Wainwright notice terminating the October 4, 2024 ATM agreement effective November 16, 2026, with no termination penalties.
Analysis · EDSA · Life Sciences
Edesa has handed Kyorin exclusive Japanese rights to paridiprubart (EB05) for ARDS, securing $12 million in cash up front plus up to $55 million in development and regulatory milestones and up to ¥12.0 billion in sales milestones—roughly $134 million in total potential milestones per the release—with low double-digit tiered royalties on Japanese sales. For a company that warned in its August 10-Q that resources would not fund operations through fiscal 2026, $12 million of non-dilutive cash is the difference between needing another discounted equity raise and having room to run. Edesa keeps all rights outside Japan and retains manufacturing, so the U.S. and Europe value remains intact. The same 8-K also terminates the H.C. Wainwright ATM agreement effective November 16, 2026, with no termination penalties—removing a standing dilution tap just as non-dilutive cash arrives.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 51.3% of the 191 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.73%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EDSA was trading at $2.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28.9M. The 52-week trading range was $0.72 to $20.32. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.